For more than a decade, CRISPR has shaped global conversations around gene editing. Its arrival made it easier for scientists to work with DNA, creating new possibilities in agriculture, healthcare, and industrial biotechnology. Yet, even with its advantages, researchers have continued searching for tools that are more compact, more precise, and easier to deliver into plant and animal cells.
In India, that search has led to a significant development. Scientists at ICAR–Central Rice Research Institute (CRRI) in Cuttack have created a gene-editing tool based on TnpB or Transposon-associated proteins, an ancient protein considered an evolutionary precursor to the CRISPR-Cas systems we know today. Their work has now secured an Indian patent under the title “Systems and Methods for Targeted Genome Editing in Plants,” marking a moment of scientific confidence for the country’s biotechnology community.
The emergence of this TnpB-based system does not seek to replace CRISPR overnight. Instead, it adds a fresh, domestically developed option that could make gene editing more accessible to Indian researchers, start-ups, and agricultural institutions.
How CRISPR Became the Centre of Modern Gene Editing
CRISPR-Cas9 has been widely embraced because of its relative simplicity: a large protein guided by a short RNA molecule can locate a specific DNA sequence and make a precise cut. Over the years, this method has been used to improve crop traits, study human diseases, develop diagnostics, and engineer microbes for industrial processes.
But the system is not without challenges. Cas proteins, such as Cas9 and Cas12a, are large—around 1300 amino acids—which makes their delivery into certain cells difficult. There are IP complexities as well, with patents split across international institutions. Many Indian organisations must navigate costly licenses or restrictive agreements to use CRISPR at scale. And in some applications, off-target edits remain an area of scientific scrutiny.
These limitations are why alternative gene-editing systems—smaller, simpler, and more adaptable—are being actively explored across the world.
What Makes TnpB Unique and Why India Is Paying Attention
TnpB is a compact nuclease associated with mobile genetic elements. For years, it existed in scientific literature largely as a curiosity—a minimalistic ancestor of modern CRISPR systems. But scientists at ICAR–CRRI saw promise where others saw an evolutionary remnant.
Their version of TnpB is just 408 amino acids long—roughly one-third the size of Cas9 or Cas12a. Its small size makes it more suitable for virus-mediated delivery, a method commonly used in plant transformation and gene therapy research.
The development carries weight for India because it is both home-grown and officially patented. It means Indian institutions have the freedom to use, refine, and commercialise the tool without negotiating complex external IP. This shift in ownership is important in a country where agricultural and medical innovation often depends on accessible technology.
Speaking about the invention, Kutubuddin Ali Molla, senior scientist at ICAR’s Central Rice Research Institute (CRRI) in Cuttack, Odisha and lead inventor of the technology, explained its significance, “What we have developed is a new GE system based on TnpB, instead of Cas proteins. It offers an alternative, yet highly effective next-generation tool for genome editing in plants.”
Comparing CRISPR and TnpB Through a Practical Lens
Although both CRISPR-Cas9 and TnpB rely on RNA-guided mechanisms to target specific DNA sequences, their structural and functional properties differ.
CRISPR-Cas9 remains robust and widely validated. It has a decade of global research behind it, with established protocols across crops, microbes, and animal systems. Researchers know its strengths and work continuously to overcome its limitations.
TnpB, however, offers a compact alternative. Its small size expands the possibilities for efficient delivery, especially in plant systems where transformation can be challenging. In early results, the ICAR–CRRI team demonstrated editing efficiency of up to 69% in rice (a monocot) and Arabidopsis (a dicot). They also reported successful multiplex editing—targeting multiple genes simultaneously—and base editing, which allows fine-tuned changes at the level of individual nucleotides.
These results do not immediately place TnpB above CRISPR, but they suggest a promising tool with practical advantages. Crucially, the newly patented TnpB system positions India to contribute directly to next-generation gene-editing technologies.
Also Read: SKUAST-K Hosts Workshop on ‘Genome Editing for Modern Agriculture’
What the Patent Means for India’s Scientific Landscape
The granting of the patent to ICAR–CRRI is not just a legal milestone; it is a strategic one. For years, Indian researchers have relied on licensed foreign technologies for gene editing. Owning a platform shifts the dynamics.
Indian universities and agricultural research stations can now access a gene-editing tool without worrying about multi-layered IP negotiations. Start-ups can experiment freely, reducing the financial barriers to innovation. And public research institutions can customise the tool to suit India’s diverse agricultural needs, from rice and millets to horticultural and pulse crops.
The patent strengthens India’s position in global biotechnology conversations. While other countries have pioneered CRISPR-based platforms, India now contributes a distinct alternative that is relevant not only locally but potentially internationally.
Why This Matters for Indian Agriculture
Agriculture is where TnpB’s immediate impact may be most visible. With climate change altering rainfall patterns, increasing salinity in coastal soils, and intensifying pest pressures, Indian breeders are under pressure to develop resilient crop varieties quickly.
Gene editing, especially when it does not involve inserting foreign DNA, offers a path to faster, precise crop improvement. The compact TnpB system allows efficient delivery into plant cells, potentially making transformation pipelines more reliable. Early demonstrations of performance in both rice and Arabidopsis indicate that the tool may be versatile across monocots and dicots.
This opens possibilities for enhancing traits such as drought tolerance, improved grain quality, nitrogen-use efficiency, disease resistance, and shelf-life stability. For farmers, the benefits would translate into more dependable harvests. For researchers, the technology lowers barriers to entry. And for India’s agri-tech sector, it provides an IP-safe foundation on which to build products tailored to Indian needs.
Potential Applications in Healthcare and Industrial Biotechnology
Although the current patent and experiments focus on plants, the compact nature of TnpB invites curiosity from other fields. In gene therapy research, size constraints often make delivery difficult. A smaller nuclease expands design space in viral vectors. Indian biotech start-ups exploring microbial engineering, diagnostics, or therapeutic research may eventually find applications for TnpB-inspired systems outside agriculture.
That said, any medical application would require years of careful study, ethical review, and regulatory oversight. The responsible path forward would involve transparent data, safety assessments, and public conversations about benefits and risks.
Head-to-Head: TnpB vs. CRISPR-Cas9 at a Glance
To understand the key differences, it’s helpful to see the two systems side-by-side.
| Feature | CRISPR-Cas9 | TnpB System |
| Size (Protein Length) | ~1300 amino acids | 408 amino acids |
| Origin / Maturity | Established for over a decade with widely validated protocols | Based on an ancient protein; newly developed as a tool with promising early results |
| Intellectual Property (IP) | Complex international patents requiring licenses | Home-grown Indian patent, offering accessible use for Indian institutions |
| Primary Advantage | Robust, widely validated, and supported by a decade of global research | Compact size for efficient delivery and IP freedom for Indian innovation |
Challenges That Still Demand Attention
Despite its promise, the TnpB system is still in its early chapters. Several hurdles lie ahead. Extensive validation across crop species is necessary before large-scale deployment. Researchers will need to assess off-target effects, editing stability, and the behaviour of the nuclease across environmental conditions.
There is also the need for capacity building. Many agricultural universities and labs lack equipment or training for advanced molecular work. Ensuring equitable access will be as important as the technology itself.
Finally, regulatory clarity will determine how smoothly the system moves from the lab to the field. India has taken steps toward supporting gene editing, but policies must keep pace with emerging tools to provide scientific, ethical, and commercial certainty.
A Moment of Possibility for India’s Bioeconomy
CRISPR is not being replaced; it remains indispensable across scientific fields. TnpB, however, gives India a valuable addition—compact, adaptable, and domestically owned. The early results from ICAR–CRRI, combined with patent protection and growing scientific interest, offer a sense of momentum.
As Indian researchers continue to refine the tool and explore its applications, the coming years will reveal how TnpB fits into the broader landscape of gene editing. Whether in agricultural fields in Odisha, biotech hubs in Bengaluru, or classrooms in state agricultural universities, this technology represents a thoughtful step toward India shaping its own path in modern genome engineering.
